Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV
Status:
Recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
Nausea and vomiting caused by chemotherapy are considered by patients as the main side
effects of cancer treatment, which affect the quality of treatment and life.At present, NCCN
guidelines have recommended three or four drug regimens for highly emetic chemotherapy (HEC)
to prevent vomiting, all containing dexamethasone.However, its side effects such as moderate
to severe insomnia, hyperglycemia, dyspepsia, upper abdominal discomfort, irritability,
increased appetite, weight gain and acne are gathering increasing concerns.For certain
patients, the use of dexamethasone should be avoided.Analysis shows that olanzapine can
replace the effect of dexamethasone.Hence, we initiated this prospective, multi-center, phase
III study to validate the dexamethasone-free protocol: removing dexamethasone from a three
drug regimen containing olanzapine, dexamethasone, and 5-HT3RA.